2023 Oncolytic Viruses Landscape Review

The oncolytic virus space has faced its fair share of skepticism in recent years, yet 2023 showcased a milestone. It marked the year that the largest number of trials both started and ended. This indicates that the field may not be facing as many challenges as previously perceived. Our Oncolytic Viruses team have compiled a thorough review of the 2023 landscape, featuring crucial highlights on drugs, trials, future projections, and our latest addition of deals and companies insights. With this comprehensive report, you’ll gain unparalleled visibility into the realm of oncolytic viruses.

Obtain your copy of the report for an thorough analysis of the current landscape, a summary of regulatory announcements in 2023, and valuable insights into the future of oncolytic viruses.

Download Here

Uncover the 2023 Oncolytic Viruses Landscape

A comprehensive analysis of the drugs, trials, deals, and companies’ landscapes for the Oncolytic Viruses space and regulatory announcements from 2023.

Download Here

About the 2023 Landscape Review

With over 600 oncolytic viruses assets being tracked on our database, some highlights include the surge of Rhabdoviridae viruses as the fastest-growing viral family despite their relatively smaller presence in the overall family space. This shift underscores the evolving nature of virus family data since our last landscape review.

Furthermore, with oncolytic viruses being genetically modified as the leading approach to target cancer cells, you will have the opportunity to delve deeper and uncover which type of genetic modification holds the largest number of assets.

Excited to explore further? If you wish to see an in-depth breakdown of the information above, you can download the 2023 Oncolytic Viruses Landscape report.

Find out more

Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.

Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts. Beacon is here to support you in making these decisions with confidence through our encompassing database solution.

With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.

Discover a database tailored to your needs